Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.

Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw.

J Clin Densitom. 2017 Jan - Mar;20(1):8-24. doi: 10.1016/j.jocd.2016.09.005. Epub 2016 Dec 9. Review.

PMID:
27956123
2.

Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia.

Forestier-Zhang L, Watts L, Turner A, Teare H, Kaye J, Barrett J, Cooper C, Eastell R, Wordsworth P, Javaid MK, Pinedo-Villanueva R.

Orphanet J Rare Dis. 2016 Nov 28;11(1):160.

3.

The RUDY study platform - a novel approach to patient driven research in rare musculoskeletal diseases.

Javaid MK, Forestier-Zhang L, Watts L, Turner A, Ponte C, Teare H, Gray D, Gray N, Popert R, Hogg J, Barrett J, Pinedo-Villanueva R, Cooper C, Eastell R, Bishop N, Luqmani R, Wordsworth P, Kaye J.

Orphanet J Rare Dis. 2016 Nov 8;11(1):150.

4.

Response to comments on "diagnosis and management of osteoporosis of the jaw: a systematic review and international consensus".

Khan A, Morrison A, Ruggiero S, Tetradis S, Davison KS, Peters E, Compston J; International ONJ Task Force.

J Bone Miner Res. 2015 Jun;30(6):1116-7. doi: 10.1002/jbmr.2524. Epub 2015 May 1. No abstract available. Erratum in: J Bone Miner Res. 2015 Oct;30(10):1941.

5.

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw.

J Bone Miner Res. 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405. Review.

6.

Osteoporosis in men: an Endocrine Society clinical practice guideline.

Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS; Endocrine Society.

J Clin Endocrinol Metab. 2012 Jun;97(6):1802-22. doi: 10.1210/jc.2011-3045.

PMID:
22675062
7.

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.

Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; HORIZON Pivotal Fracture Group.

J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292.

8.

Bisphosphonates for postmenopausal osteoporosis.

Eastell R, Walsh JS, Watts NB, Siris E.

Bone. 2011 Jul;49(1):82-8. doi: 10.1016/j.bone.2011.02.011. Epub 2011 Feb 22. Review.

PMID:
21349354
9.

Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence.

Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB.

J Bone Miner Res. 2011 Jul;26(7):1662-9. doi: 10.1002/jbmr.342.

10.

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.

Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial.

Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9. Epub 2009 Oct 3.

11.

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial.

J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30.

12.

Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.

Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R; HORIZON-PFT Research Group.

J Bone Miner Res. 2009 Sep;24(9):1544-51. doi: 10.1359/jbmr.090310.

13.

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP; Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators.

J Clin Endocrinol Metab. 2008 Oct;93(10):3785-93. doi: 10.1210/jc.2008-0353. Epub 2008 Aug 5.

14.

Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.

Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB; Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators.

J Clin Endocrinol Metab. 2007 Apr;92(4):1296-304. Epub 2007 Jan 23. Erratum in: J Clin Endocrinol Metab. 2007 Jun;92(6):2285.

PMID:
17244788
15.

Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study.

Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, Cahall DL; IMPACT Study Group.

J Bone Miner Res. 2005 Apr;20(4):557-63. Epub 2004 Dec 6.

16.
17.

Efficacy of risedronate on clinical vertebral fractures within six months.

Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D, Songcharoen S, Rizzoli R, Di Munno O, Horlait S, Valent D, Watts NB.

Curr Med Res Opin. 2004 Apr;20(4):433-9.

PMID:
15119979
18.

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW.

Arch Intern Med. 2004 Apr 26;164(8):871-9.

PMID:
15111373
19.

Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline.

Vesper HW, Demers LM, Eastell R, Garnero P, Kleerekoper M, Robins SP, Srivastava AK, Warnick GR, Watts NB, Myers GL.

Clin Chem. 2002 Feb;48(2):220-35. Review.

Supplemental Content

Loading ...
Support Center